US 12,076,382 B2
Combination immunotherapy compositions against cancer and methods
James Hodge, Kensington, MD (US); Jeffrey Schlom, Potomac, MD (US); and Alex Franzusoff, Los Altos, CA (US)
Assigned to GlobeImmune, Inc., Louisville, CO (US); and The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed by GLOBEIMMUNE, INC., Louisville, CO (US); and The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Jan. 24, 2023, as Appl. No. 18/158,800.
Application 18/158,800 is a continuation of application No. 17/130,551, filed on Dec. 22, 2020, granted, now 11,590,216.
Application 17/130,551 is a continuation of application No. 16/951,739, filed on Nov. 18, 2020, granted, now 11,596,675.
Application 16/951,739 is a continuation of application No. 16/458,726, filed on Jul. 1, 2019, granted, now 10,874,729, issued on Dec. 29, 2020.
Application 16/458,726 is a continuation of application No. 13/264,846, granted, now 10,383,924, issued on Aug. 20, 2019, previously published as PCT/US2010/031460, filed on Apr. 16, 2010.
Claims priority of provisional application 61/170,530, filed on Apr. 17, 2009.
Prior Publication US 2023/0256067 A1, Aug. 17, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 31/00 (2006.01); A61K 38/00 (2006.01); A61K 38/19 (2006.01); C07K 14/47 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 39/001102 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001151 (2018.08); A61K 39/001152 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001162 (2018.08); A61K 39/001164 (2018.08); A61K 39/001168 (2018.08); A61K 39/00117 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 2039/523 (2013.01); A61K 2039/55522 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. A pharmaceutical composition for use in the prevention or treatment of at least one symptom of a disease or condition in an individual, the composition comprising two immunotherapy compositions for administration within a dosing period, the two immunotherapy compositions comprising:
a) a first immunotherapy composition comprising a recombinant Ad5 adenovirus comprising a nucleic acid sequence encoding one or more peptides derived from one or more proteins; and
b) a second immunotherapy composition comprising either a whole inactivated yeast or yeast lysate.